Sagimet reports 52-week positive results for denifanstat extension trial
Sagimet says its license partner Ascletis presented positive full 52-week results from a Phase 3 open-label extension clinical trial of denifanstat in acne at EADV 2026.
Sagimet says its license partner Ascletis presented positive full 52-week results from a Phase 3 open-label extension clinical trial of denifanstat in acne at EADV 2026.